In their network meta-analysis (NMA), Rochwerg and colleagues (1) concluded that albumin is superior to crystalloids and starches. However, their review did not include several studies that directly compare albumin with other fluids. Therefore, we did an updated meta-analysis based on a previous one (2).
IN RESPONSE:
We thank Dr. Zhang and colleagues for their points about the administration of albumin for resuscitation in patients with sepsis. The methods of their meta-analysis differ from those of ours in several respects, and it is thus unsurprising that our results are discordant. We used an NMA framework that has the advantage of incorporating indirect evidence as opposed to only direct evidence as in a conventional meta-analysis.
We excluded the ALBIOS (1) and EARSS (2) studies because albumin administration in these trials was independent of hemodynamic instability and the focus of our NMA was resuscitation fluid. We included the CRISTAL study (3) only in the pairwise meta-analysis of colloids versus crystalloids because patients were randomly assigned to receive any colloids or any crystalloids. Although the CRISTAL study presented results based on the specific fluid received, this factor was not a randomization characteristic; accordingly, we did not integrate these data in our NMA because of the potential for bias. Finally, we included the SAFE study (4) , whereas Dr. Zhang and colleagues excluded it for unclear reasons.
We agree that, for most patients with sepsis, the first choice of resuscitative fluid should be crystalloids. The results of our NMA suggest that a "balanced" crystalloid solution with a more physiologic chloride concentration may be preferred, but we believe that more research is needed to confirm or refute this finding (5) .
Although the CIs around the mortality estimate comparing albumin with any crystalloid (NMA odds ratio, 0.83 [95% credible interval, 0.65 to 1.04]) include the potential that albumin confers a mortality benefit, this factor must be balanced against important considerations of cost and transfusion risk. Our results show that albumin seems to be at worst similar to crystalloids with respect to mortality risk. When albumin is used for resuscitation, research is sparse to guide the choice of dose, concentration, or timing.
Presently, we do not advocate that albumin be used as a first choice for resuscitation in sepsis. However, until further research becomes available suggesting otherwise, we believe that it is reasonable to include it as 1 potential resuscitative fluid. Meanwhile, in clinical practice, most patients will continue to receive a combination of fluids for resuscitation rather
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Rethinking the Use of Physicians as Hired Expert Lecturers TO THE EDITOR: Avorn's commentary (1) mentions GlaxoSmithKline's (GSK's) retreat from support of physician lecture programs. We find the drug company's actions lamentable, particularly at a time when the introduction of novel pharmaceuticals with complex mechanisms of action and clinicians' desire for education have never been greater.
In 2014, the U.S. Food and Drug Administration (FDA) approved 41 new drugs, many of them completely novel. Commercially supported physician lectures answer an urgent need for high-quality information about new drugs from experienced peers. The content of these programs is rigorous and satisfies the FDA's stringent requirements for accuracy, objectivity, fair balance, and reliance on well-controlled studies. Commercial interests are fully disclosed, and layers of oversight-from corporate integrity agreements and adherence to the U.S. Department of Health and Human Services Office of Inspector General guidelines (2) and the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals (3)-protect prescribers and patients from unsupported claims that could lead to inappropriate use.
In contrast, non-commercially sponsored lecturers, including academicians and other key opinion leaders, typically are accountable only to themselves and their institutions. These speakers may lack legal compulsion to disclose conflicts of interest and be motivated by drug costs, politics, a desire for peer admiration, or fear of change. Little prevents them from advocating uses not proved to meet the FDA's standards of safety and efficacy.
Absence of commercial sponsorship does not ensure freedom from bias, nor does commercial support necessarily compromise objectivity. Medical, legal, engineering, and accountancy journals, for example, have long enjoyed subsidy provided by their advertising pages while trusting their readership to discern information from promotion.
In a recent independent survey of 500 clinicians, more than 90% responded that they found information provided by sponsored speakers to be timely, useful, and reliable; 94% agreed that these programs improved their care for patients (4) . Clinicians also show that they value commercially sponsored speaker programs for the information provided, not "complimentary meals." According to Manhattan Research, 71% of physicians participated in online medical conferences last year (5) .
High-quality medical education programs require substantial expertise, time, and other resources to produce. Further declines in commercial support for them would seriously compromise physician knowledge and, ultimately, patient care. We hope that other pharmaceutical manufacturers do not follow GSK's lead and that GSK rethinks this unfortunate decision. 
TO THE EDITOR:
GlaxoSmithKline is an internationally renowned pharmaceutical agency, and we believe that their recent decision to discontinue hiring physicians as expert lecturers as described in Avorn's commentary (1) has significant consequences. The author presumes that physicians' desire to lecture is due to the monetary reward. However, a study of senior Norwegian medical students found that only 17.5% had a positive attitude toward the pharmaceutical industry, and most said that they would decline monetary gifts (2) . This study shows that the new generation of physicians is less influenced by a drug company's monetary offers than previous generations. Therefore, GSK's plan to stop hiring physicians as expert lecturers could mean that future physicians who truly had a desire to educate could potentially miss out on opportunities to teach and share their knowledge. GlaxoSmithKline could combat this loss by assessing physicians' teaching content beforehand.
Avorn mentions that "academic detailing" is an excellent alternative to educate physicians about evidence-based prescribing free of commercial influences (3). Implementing such methods opens new pathways for physicians to learn while being influenced not by drug companies but rather by the evidence behind drugs. However, evidence-based prescribing cannot replace the knowledge or skills taught by expert lecturers.
One argument Avorn poses is that "physician performance of paid speaking engagement seems to be diminishing" (1) . First, in the same way that fewer physicians are accepting paid speaking engagements, fewer teachers in medical and pharmacy schools are solely educators and more educators also work as practicing physicians. A study of pharmacy students in Saudi Arabia concluded that 53.7% preferred a direct type of lecturing and that their aid for revision was handouts made by the lecturers (4). Second, postgraduates who have had training and feedback from physicians in terms of their practical skills do better in Objective Structured Clinical Examinations (5). This finding shows that performance is not diminishing but that practicing physicians are used to being taught by colleagues and subsequently trust information provided by them.
Because physicians will be the front-line prescribers, it is logical that they would educate their peers. It is a shame that GSK is no longer using such a good resource, because we believe that physicians provide pharmaceutical knowledge in a more clinically oriented way.
Kaenat Mulla Adebusola Shonubi, iBSc Dev Katarey, BMBS, MSc
St. George's University of London London, United Kingdom TO THE EDITOR: I read Avorn's commentary (1) with great interest. As far I can remember, great ideas didn't come preprinted in journals or textbooks. They come from free minds speaking without restrictions about a subject or an issue while sipping a cup of coffee or sharing lunch or a drink. To suggest that respected, well-paid physicians would change their practicing behavior and put aside their patient care just for a meal is demeaning. It is not relevant who pays for a dinner and who sponsors it. What's more important is that it's an effort to get a few physicians to start talking about clinical care in the context of a new therapy that might help their patients. Thanks to the bureaucracy of a few, this opportunity is now lost. IN RESPONSE: Dr. Garnick and Ms. Balter argue that we should be grateful that drug companies hire physicians to teach us about the many new drugs that are introduced annually. But the purpose of such talks, often arranged through a company's marketing department, is primarily to increase product sales rather than present a comprehensive view. It is unrealistic to expect these presentations to emphasize that a generic medication may be as effective as the sponsor's more expensive product or have a longer safety track record (1). Several major investigations and more than $15 billion in settlements have documented widespread violations of guidelines because companies promoted uses of their drugs that were poorly justified, dangerous, or both (2) . The unpublished industry survey that Dr. Garnick and Ms. Balter cite found that 75% of physicians said that they receive information about prescribing choices through company-sponsored programs that do not offer continuing medical education credits and feature hired physician-speakers-not a statistic to be proud of (3) .
Of course, we academic physicians also have biases and conflicts, but claiming that the information provided by physicians who are not paid by the pharmaceutical industry is inherently less reliable than that provided by company spokespersons is simply implausible. A recent survey of 2336 medical students and residents found that those who relied more on company-sponsored information were significantly less likely to provide evidence-based answers to prescribing questions and significantly more likely to recommend brandname products than generic ones (4). Non-industrysupported sources of information are a better way to meet the profession's growing need to assimilate data on the comparative effectiveness of medications (5).
Ms. Mulla and colleagues worry that a reduction in pharmaceutical payments to physicians will decrease physicians' involvement in teaching. Fortunately, clinicians' participation in educating our peers and students is a well-established tradition in medicine that will continue even if drug manufacturers don't pay us to do so.
Dr. Khan is concerned that GSK's plan to withdraw funding for sponsored lectures will mean that physicians will no longer be able to meet to discuss new drugs that may benefit their patients. Of course we will; we'll just have to pay for our own food.
As a nation, we have accepted the false economy that it is a bargain to accept "free" medical education from drugmakers about their products. Such bargains can only exacerbate our per capita drug spending, which is the highest in the world. With growing concern about providing safe, effective, and affordable drug regimens, now is a good time to rethink who should be defining our understanding of the medications that we prescribe.
Jerry Avorn, MD Harvard Medical School and Brigham and Women's Hospital Boston, Massachusetts
Background: An elevated plasma osmolal gap is common in all forms of alcohol intoxication. Methyl alcohol and ethylene glycol are metabolized to compounds that produce metabolic acidosis. Isopropyl alcohol, however, is metabolized to acetone, which does not cause metabolic acidosis and cannot be metabolized to compounds that do (1) . Therefore, the presence of metabolic acidosis is used to rule out isopropyl alcohol intoxication. This distinction is important because fomepizole is used to treat methyl alcohol and ethylene glycol intoxication but is contraindicated in isopropyl alcohol intoxication because it reduces the clearance of isopropyl alcohol and thus prolongs its effects (2) .
Objective: To describe a patient with isopropyl alcohol intoxication and metabolic acidosis.
Case Report: A 45-year-old woman with a history of alcohol abuse came to the emergency department with confusion, agitation, and chest pain. She described drinking large amounts of alcohol during the previous 2 weeks but no alcohol during the past 2 days. An evaluation for the acute coronary syndrome was negative. She had a wide plasma osmolal gap (44 mmol/kg) and anion gap metabolic acidosis (15 mmol/L) with elevated serum ␤-hydroxybutyric acid levels (3620 μmol/L), normal serum lactate levels, and negligible serum salicylate and ethyl alcohol levels. The urinary acetone level was elevated (at least 80 mg/dL, the highest level that our assay could measure). We diagnosed methyl alcohol or ethylene glycol intoxication, considering the history of alcohol abuse, wide osmolal gap, metabolic acidosis, and normal serum ethyl alcohol levels. We administered a loading dose of 15 mg/kg of fomepizole.
Ten hours later-shortly before the next dose of fomepizole-the patient remained confused, which we interpreted as failure to respond. A screening test of the patient's blood for volatile chemicals found elevated levels of isopropyl alcohol (1.69 mmol/L) and acetone (38 mmol/L), with negligible levels of ethyl alcohol, methyl alcohol, and ethylene glycol. On further questioning, the patient described drinking rubbing alcohol and eating little food for several days. We discontinued fomepizole therapy and continued supportive therapy. She improved over 24 hours, developed alcohol withdrawal symptoms that responded to treatment, and returned to baseline mental and functional status after 3 days.
Discussion: This patient had isopropyl alcohol intoxication. We believe that she also had alcoholic ketoacidosis, which occurs when persons who chronically abuse ethyl alcohol suddenly decrease their calorie intake (3). The unexpected metabolic acidosis prevented us from initially recognizing the possibility of isopropyl alcohol intoxication, although in retrospect the high levels of urinary acetone might have alerted us to this condition.
Our experience shows that isopropyl alcohol intoxication combined with alcoholic ketoacidosis can be misdiagnosed as ethyl or methyl alcohol or ethylene glycol intoxication. This possibility is not widely appreciated in the medical literature; for example, it is not mentioned in UpToDate, a frequently used electronic textbook of medicine (4) . It is important for clinicians to note that the laboratory findings of alcoholics who drink isopropyl alcohol and have reduced caloric intake are similar to those of alcoholics who consume ethyl or methyl alcohol or ethylene glycol. Therefore, we advise clinicians to consider isopropyl alcohol intoxication in patients who have a high osmolal gap with anion gap metabolic acidosis. In the third row of boxes in the Figure on ITC10 , the first box should have a greater than/equal to sign and the second box should have a less than sign. The arrow to the next step is missing from the blood pressure goal boxes to the following step. The corrected figure appears below.
On page ITC11, amlodipine is a dihydropyridine calciumchannel blocker as opposed to a nonhydropine calciumchannel blocker, as implied by the heading.
This has been corrected in the online version.
